Reconnecting

The current page stays visible while onset.to reconnects in the background.

HLP003 shows a 7.6-point depression score advantage in Phase 3, with replication and retreatment still to be tested

Open original

Two 16 mg doses of HLP003, a deuterated form of psilocin, reduced depression scores by 7.6 points more than placebo at Week 6 and 7.0 points more at Week 12 in a 222-person Phase 3 trial. Participants had major depressive disorder and remained on a stable antidepressant. Three treatment-related serious adverse events were reported in the HLP003 group: two cases of depression and one suicide attempt. The inactive placebo raises questions about whether participants recognized their assignments; no treatment-guess or expectancy data were published. The trial did not isolate the second dose's contribution or establish retreatment frequency. A second pivotal trial is expected to report in late 2027, while an open-label extension will examine longer-term outcomes and retreatment.